The present invention relates to the use of cells having discernible surface protein with engineered or naturally occurring mutation(s) but functional surface protein for use in therapy. The present invention also relates to the use of cells having discernible CD123 surface protein variants but functional surface protein for use in therapy, in particular adoptive cell therapy.

DISCERNIBLE CELL SURFACE PROTEIN VARIANTS FOR USE IN CELL THERAPY / Lepore, R; Jeker, L; Urlinger, S; Landmann, E; Sinopoli, A; Wiederkehr, A; Devaux, A; Camus, A; Haydn, A; MATTER-MARONE, R. - (2022).

DISCERNIBLE CELL SURFACE PROTEIN VARIANTS FOR USE IN CELL THERAPY

LEPORE R;
2022

Abstract

The present invention relates to the use of cells having discernible surface protein with engineered or naturally occurring mutation(s) but functional surface protein for use in therapy. The present invention also relates to the use of cells having discernible CD123 surface protein variants but functional surface protein for use in therapy, in particular adoptive cell therapy.
2022
Cell Therapy, Protein Engineering, Monoclonal Antibody
05 Brevetto::05a Brevetto
DISCERNIBLE CELL SURFACE PROTEIN VARIANTS FOR USE IN CELL THERAPY / Lepore, R; Jeker, L; Urlinger, S; Landmann, E; Sinopoli, A; Wiederkehr, A; Devaux, A; Camus, A; Haydn, A; MATTER-MARONE, R. - (2022).
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1680144
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact